BRAVELLE
LOE ApproachingBLAINTRAMUSCULAR, SUBCUTANEOUSINJECTABLE
Approved
May 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BRAVELLE is an injectable biologic (BLA) developed by Ferring Pharmaceuticals and approved in 2002, indicated for reproductive/fertility applications. The product is administered via intramuscular or subcutaneous injection. Specific mechanism of action data is not available in current records.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30), signaling smaller team size and focus on retention strategies over growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BRAVELLE offers limited growth potential given LOE approaching status and zero linked job openings. Positions are likely focused on maintaining market share, managing provider relationships, and preparing commercial transitions rather than expansion.
Brand ManagerField Sales Representative
Worked on BRAVELLE at Ferring Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.